New Experimental Pain Relief Drug Shows Promise

A novel drug, SBI-810, has been developed with the potential to provide significant pain relief without the dangerous and addictive side effects commonly associated with opioids. It specifically targets a single receptor pathway in the brain that is linked to pain alleviation, distinguishing itself from opioids by sidestepping the euphoric sensations and serious complications often tied to those substances.

In studies involving mice, SBI-810 effectively eased pain resulting from surgeries, fractures, and nerve injuries. Moreover, it appeared to enhance the effects of opioids at lower doses without leading to tolerance—a common issue with traditional opioid treatments. The drug also showed better results than current medications like gabapentin, achieving this without causing sedation or memory issues. Its mechanism involves activating a receptor known as neurotensin receptor 1 through a method called biased agonism, providing pain relief via a safer signaling pathway.

Key Points

• Focused Action: SBI-810 selectively activates a specific pain-relief pathway (β-arrestin-2) without interfering with pathways associated with addiction.
• No Development of Tolerance: Mice administered SBI-810 did not develop tolerance or experience common adverse effects like sedation or memory loss.
• Increased Efficacy: The drug not only alleviated various pain types but also improved the effectiveness of opioids at safer, reduced doses.

This experimental drug, created at Duke University School of Medicine, represents a shift in how pain might be treated. Unlike typical opioids that affect multiple cellular pathways indiscriminately, SBI-810 is a non-opioid solution that zeroes in on a particular pain-relief pathway, effectively bypassing the euphoric high often linked with addiction.

In animal testing, SBI-810 showed promise on its own and, when combined with opioids, made them work more efficiently at lower doses, as detailed in a recent publication in Cell.

According to Ru-Rong Ji, PhD, who spearheaded the research, this compound is noteworthy for being both an analgesic and a non-opioid, which is indeed quite exciting.

Encouragingly, the drug limited common opioid side effects, like constipation and the need for escalating doses over time, a typical problem for patients relying on opioids to manage pain. While SBI-810 is still in its early stages, researchers at Duke are hopeful about moving to human trials soon and have secured several patents related to their findings.

The need for effective pain management alternatives is pressing. Even though drug overdose deaths are on the decline, around 80,000 Americans still lose their lives each year due mainly to opioids. Chronic pain, on the other hand, affects a significant portion of the U.S. population—about one in three individuals.

Experts believe that SBI-810 could safely address both acute and chronic pain, benefiting individuals recovering from surgeries or those suffering from diabetic nerve pain.

SBI-810 works by targeting the neurotensin receptor 1 in the brain. Using biased agonism, it activates a particular pathway—β-arrestin-2—related to pain relief, while steering clear of pathways known to cause side effects or addiction.

Ji points out that this receptor is present on sensory neurons in both the brain and spinal cord, which makes it a promising target for managing both acute and chronic pain scenarios.

The effectiveness of SBI-810 in alleviating pain from surgical processes, fractures, and nerve damage was noted to be higher than that of some current pain relief options. In mice, it significantly reduced signs of discomfort like grimacing and guarding behavior.

Additionally, when compared to oliceridine, a newer opioid utilized in hospitals, SBI-810 demonstrated superior performance in several cases with fewer signs of distress.

Notably, SBI-810 does not result in tolerance with repeated use—a clear advantage over drugs like morphine. It also surpassed gabapentin in efficacy, avoiding sedation or memory issues that often arise with that medication.

The dual action of SBI-810—impacting both peripheral and central nervous systems—may pave the way for a new balance in pain management: effective yet safe.

Funding

The research was funded by the NIH and the Department of Defense.